Stephen T Durant
7PUBLICATIONS
64CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Aug 16, 2023
ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.Ben Yi Tew, Alex J Kalfa, Zeyi Yang
|Feb 01, 2023
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.Haojian Li, Yue Liu, Yunjie Xiao
|Nov 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.Massimiliano Mellone, Klaudia Piotrowska, Giulia Venturi
|Aug 19, 2021
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.Balakrishna Koneru, Ahsan Farooqi, Thinh H Nguyen
|Jan 10, 2019
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.Gabriel Balmus, Domenic Pilger, Julia Coates
|Jun 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.Stephen T Durant, Li Zheng, Yingchun Wang
Pageof 2
Frequent Collaborators
2 joint publications
Venkatesh Pilla Reddy
1 joint publications
Massimiliano Mellone
1 joint publications
Klaudia Piotrowska
1 joint publications
Giulia Venturi
1 joint publications
Lija James
1 joint publications
Aleksandra Bzura
1 joint publications
Maria A Lopez
1 joint publications
Sonya James
1 joint publications
Chuan Wang
1 joint publications
Matthew J Ellis
